Adiponectin’s protective effects for T2D development may be less effective in a state of chronic inflammation caused by high adiposity, which is thought to be partially explained by adiponectin resistance, a condition usually seen along with insulin resistance and a decline in adiponectin receptor (AdipoR1/R2) mRNA expression. Here, ADIPOQ is linked to type 2 diabetes mellitus.